Antibacterial and antimycobacterial products for systemic use
Finnish Institute for Health and Welfare · koko Suomi
Perustiedot
- Hankkija
- Finnish Institute for Health and Welfare, Y-tunnus 2229500-6
- Toteutuspaikka
- koko Suomi
- Hankintalaji
- Tavarahankinta
- Menettely
- Avoin menettely, EU-hankinta
- Ilmoituksen tyyppi
- Jälki-ilmoitus
- Sopimusten kokonaisarvo
- 1 € (alv 0 %)
- Erät
- 10 erää
- Pääasiallinen CPV
- 33651000 Systeemisesti vaikuttavat infektiolääkkeet
- Lisäkoodit: 33600000
- Sopimuskausi
- 13 kuukautta
- Julkaistu
- 2.2.2025
Hankinnan tulos
| Erä | Voittaja | Sopimusarvo | Tarjouksia | Päätös |
|---|---|---|---|---|
| Erä 1: LOT 1: Linezolid 2 mg/ml (300 ml, i.v. solution, ATC J01XX08) | FrostPharma AB | 1 € | ei ilmoitettu | |
| Erä 2: LOT 2: Pyrazinamide 500 mg (tablet/capsule, oral, ATC J04AK01) | Orion Oyj, Y-tunnus 1999212-6 | 1 € | ei ilmoitettu | |
| Erä 3: LOT 3: Etambuthol 500 mg (tablet/capsule, oral, ATC J04AK02) | Orion Oyj, Y-tunnus 1999212-6 | 1 € | ei ilmoitettu | |
| Erä 4: LOT 4: Clindamycin 300 mg (tablet/capsule, oral, ATC J01FF01) | EQL Pharma AB | 1 € | ei ilmoitettu | |
| Erä 5: LOT 5: Isoniazide 300 mg (tablet/capsule, oral, ATC J04AC01) | Orion Oyj, Y-tunnus 1999212-6 | 1 € | ei ilmoitettu | |
| Erä 6: LOT 6: Claritromycin 250 mg (tablet/capsule, oral, ATC J01FA09) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 7: LOT 7: Clindamycin 15 mg/ml (80 ml, oral suspension, ATC J01FF01) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 8: LOT 9: Levofloxacin 500 mg (tablet/capsule, oral, ATC J01MA12) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 9: LOT 8: Moxifloxacin 400 mg (tablet/capsule, oral, ATC J01MA14) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 10: LOT 10: Claritromycin oral suspension 50 mg/ml (50 ml, oral suspension ATC J01FA09) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 |
Voittajista näytetään nimi ja Y-tunnus. ”Ei ilmoitettu” tarkoittaa, ettei ilmoituksessa ole tätä tietoa erälle tai sopimukselle.
Ilmoituksen teksti
Alkuperäinen teksti Hilmasta, muuttamattomanaFinnish Institute for Health and Welfare, later referred to as THL or Customer, requested tenders for "Antibacterial and antimycobacterial products for systemic use" to the rescEU Medical -project. The Scope of procurement is described in more detail in Annex 1.
The procurement is divided in ten (10) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots.
LOT 1: Linezolid 2 mg/ml (300 ml, i.v. solution, ATC J01XX08)
LOT 2: Pyrazinamide 500 mg (tablet/capsule, oral, ATC J04AK01)
LOT 3: Etambuthol 500 mg (tablet/capsule, oral, ATC J04AK02)
LOT 4: Clindamycin 300 mg (tablet/capsule, oral, ATC J01FF01)
LOT 5: Isoniazide 300 mg (tablet/capsule, oral, ATC J04AC01)
LOT 6: Claritromycin 250 mg (tablet/capsule, oral, ATC J01FA09)
LOT 7: Clindamycin 15 mg/ml (80 ml, oral suspension, ATC J01FF01)
LOT 8: Moxifloxacin 400 mg (tablet/capsule, oral, ATC J01MA14)
LOT 9: Levofloxacin 500 mg (tablet/capsule, oral, ATC J01MA12)
LOT 10: Claritromycin oral suspension 50 mg/ml (50 ml, oral suspension ATC J01FA09)
The minimum requirements for the products is described in Annex 1.1.
The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the Contract has been signed by contracting parties and expires when all contractual duties of the Contract have been performed.
Quantity for the products is described in Annex 7 (restricted to security classification level IV, TL IV). In addition to the quantity indicated in the Annex 7, the Customer is entitled to purchase 100 % extra to the quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option.
Please note that all times given in the Call for tenders refer to local time in Finland.
Call for tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Description of the rotation
Annex 2.1 Quality scoring table
Annex 3 Contract
Annex 4 Security annex
Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 6 Confidentiality commitment
Annex 7 Quantity of the Articles (restricted, TL IV)
Please note that the numbering of the annexes differs between the Contract and the Call for tenders. The numbering of the Annexes to the Contract is based on the order of precedence applied in the Contract.
Lisätiedot
The availability for the Annex 7 is restricted to security classification level IV (TL IV). THL will send the Annex 7 to a representative of the tenderer via encrypted email after THL has received a scanned version of the signed Confidentiality commitment (Annex 6). The signature of the Confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/5372/2.02.06/2024 / Antibacterial and antimycobacterial products for systemic use". The message shall contain name of the tenderer and email address to which the Annex 7 is to be sent.
Erien kuvaukset
Erä 1: LOT 1: Linezolid 2 mg/ml (300 ml, i.v. solution, ATC J01XX08)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Linezolid 2 mg/ml (300 ml, i.v. solution, ATC J01XX08)
- Parenteral products (intravenous administration)
- Active pharmaceutical ingredient: Linezolid
- Strength: 2 mg / ml
- Pharmaceutical form: 300 ml infusion bag
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 2: LOT 2: Pyrazinamide 500 mg (tablet/capsule, oral, ATC J04AK01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Pyrazinamide 500 mg (tablet/capsule, oral, ATC J04AK01)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Pyrazinamide
- Strength: 500 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 3: LOT 3: Etambuthol 500 mg (tablet/capsule, oral, ATC J04AK02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Etambuthol 500 mg (tablet/capsule, oral, ATC J01FF01)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Etambuthol
- Strength: 500 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 4: LOT 4: Clindamycin 300 mg (tablet/capsule, oral, ATC J01FF01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Clindamycin 300 mg (tablet/capsule, oral, ATC J01FF01)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Clindamycin
- Strength: 300 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 5: LOT 5: Isoniazide 300 mg (tablet/capsule, oral, ATC J04AC01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Isoniazide 300 mg (tablet/capsule, oral, ATC J04AC01)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Isoniazide
- Strength: 300 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 6: LOT 6: Claritromycin 250 mg (tablet/capsule, oral, ATC J01FA09)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Claritromycin 250 mg (tablet/capsule, oral, ATC J01FA09)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Claritromycin
- Strength: 250 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 7: LOT 7: Clindamycin 15 mg/ml (80 ml, oral suspension, ATC J01FF01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Clindamycin 15 mg/ml (80 ml, oral suspension, ATC J01FF01)
- Oral liquid dosage forms
- Active pharmaceutical ingredient: Clindamycin
- Strength: 15 mg/ml
- Pharmaceutical form: 80 ml oral suspension
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 8: LOT 9: Levofloxacin 500 mg (tablet/capsule, oral, ATC J01MA12)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Levofloxacin 500 mg (tablet/capsule, oral, ATC J01MA12)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Levofloxacin
- Strength: 500 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 9: LOT 8: Moxifloxacin 400 mg (tablet/capsule, oral, ATC J01MA14)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Moxifloxacin 400 mg (tablet/capsule, oral, ATC J01MA14)
- Oral solid dosage forms
- Active pharmaceutical ingredient: Moxifloxacin
- Strength: 400 mg
- Pharmaceutical form: Tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 10: LOT 10: Claritromycin oral suspension 50 mg/ml (50 ml, oral suspension ATC J01FA09)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Claritromycin oral suspension 50 mg/ml (50 ml, oral suspension ATC J01FA09)
- Oral liquid dosage forms
- Active pharmaceutical ingredient: Claritromycin
- Strength: 50 mg/ml
- Pharmaceutical form: 50 ml oral suspension
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erät
| Erä | Nimi | Ammattiala | Arvioitu arvo | CPV |
|---|---|---|---|---|
| 1 | LOT 1: Linezolid 2 mg/ml (300 ml, i.v. solution, ATC J01XX08) | – | – | 33651100 |
| 2 | LOT 2: Pyrazinamide 500 mg (tablet/capsule, oral, ATC J04AK01) | – | – | 33651300 |
| 3 | LOT 3: Etambuthol 500 mg (tablet/capsule, oral, ATC J04AK02) | – | – | 33651300 |
| 4 | LOT 4: Clindamycin 300 mg (tablet/capsule, oral, ATC J01FF01) | – | – | 33651100 |
| 5 | LOT 5: Isoniazide 300 mg (tablet/capsule, oral, ATC J04AC01) | – | – | 33651300 |
| 6 | LOT 6: Claritromycin 250 mg (tablet/capsule, oral, ATC J01FA09) | – | – | 33651100 |
| 7 | LOT 7: Clindamycin 15 mg/ml (80 ml, oral suspension, ATC J01FF01) | – | – | 33651100 |
| 8 | LOT 9: Levofloxacin 500 mg (tablet/capsule, oral, ATC J01MA12) | – | – | 33651100 |
| 9 | LOT 8: Moxifloxacin 400 mg (tablet/capsule, oral, ATC J01MA14) | – | – | 33651100 |
| 10 | LOT 10: Claritromycin oral suspension 50 mg/ml (50 ml, oral suspension ATC J01FA09) | – | – | 33651100 |
Hankinnan vaiheet
-
Tarjouspyyntö julkaistiin, määräaika 20.11.2024 klo 12.00.
-
Jälki-ilmoitustämä ilmoitus
Voittajat: FrostPharma AB, Orion Oyj ja EQL Pharma AB .
-
Aiottu toimittaja: KRKA Finland Oy.
-
Voittaja: KRKA Finland Oy.